Skip to main content

Table 5 Testing data set results a

From: Pathologic response prediction to neoadjuvant chemotherapy utilizing pretreatment near-infrared imaging parameters and tumor pathologic criteria

Tumor pathologic variables Receptors (core biopsy) Pretreatment hemoglobin parameters Sensitivity (%)/specificity (%) PPV (%)/NPV (%) AUC (%) (95% CI)
IDC/ILC, NS, MC    51.8/68.1 57.9/63.3 80.0 (51.11; 99.29)
IDC/ILC, NS, MC TN, HER2, ER   56.8/88.9 84.8/70.9 84.0 (57.16; 99.03)
   tHb 63.2/82.1 75.0/72.8 87.3 (62.13; 99.82)
   oxyHb 60.8/81.9 73.6/71.4 84.0 (56.01; 100.0)
   deoxyHb 52.2/89.6 80.4/69.1 72.2 (36.55; 97.67)
   tHb, oxyHb 64.4/82.1 75.2/73.4 85.0 (57.61; 99.82)
   tHb, deoxyHb 60.7/80.6 73.3/70.9 79.5 (56.32; 97.82)
IDC/ILC, NS, MC TN, HER2, ER tHb 78.7/93.6 89.5/85.9 92.4 (79.42; 99.80)
IDC/ILC, NS, MC TN, HER2, ER oxyHb 76.9/85.2 82.6/83.3 90.6 (74.36; 99.35)
IDC/ILC, NS, MC TN, HER2, ER deoxyHb 60.1/85.0 78.4/71.8 85.0 (58.78; 98.95)
IDC/ILC, NS, MC TN, HER2, ER tHb, oxyHb 73.2/84.9 81.8/81.7 88.6 (72.21; 97.51)
IDC/ILC, NS, MC TN, HER2, ER tHb, deoxyHb 71.5/84.3 79.5/79.1 85.0 (63.09; 99.53)
  1. aCI, confidence interval; deoxyHb, Deoxygenated hemoglobin; ER, Estrogen receptor; HER2, Human epidermal growth factor receptor 2; IDC, Invasive ductal carcinoma; IDC/ILC, Invasive mammary carcinoma with mixed ductal and lobular features; ILC, Invasive lobular carcinoma; MC, Mitotic count; NS, Nottingham score; oxyHb, Oxygenated hemoglobin; NPV, Negative predictive value; PPV, Positive predictive value; tHb, Total hemoglobin; TN, Triple-negative.